A Phase 4 interventional study of Exercise and Liraglutide in Type2 Diabetes, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by University of Virginia · Phase 4, Interventional, and Treatment
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
Our hypothesis is that sustained activation of the GLP-1 receptor with Liraglutide or exercise training will enhance microvascular perfusion, promote angiogenesis, and improve microvascular response to insulin in muscle, leading to increased muscle delivery of oxygen and nutrients and increased exercise tolerance in subjects with type 2 diabetes.
University of Virginia is the lead sponsor of 653 studies on the registry; 134 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 41 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
16 weeks of treatment
Other: Exercise
16 weeks of treatment
Drug: Liraglutide
16 weeks of treatment
Other: Exercise · Drug: Liraglutide
16 weeks of treatment
16 weeks of Liraglutide
Microvascular Blood Volume - change from baseline
measured at baseline and 16 weeks
Time frame: 16 weeks
Augmentation Index - change from baseline
measured at baseline and 16 weeks
Time frame: 16 weeks
Flow Mediated Dilation - change from baseline
measured at baseline and 16 weeks
Time frame: 16 weeks
Pulse Wave Velocity - change from baseline
measured at baseline and 16 weeks
Time frame: 16 weeks
Post Ischemic Flow Velocity-Change from baseline
measured at baseline and 16 weeks
Time frame: 16 weeks
Insulin Sensitivity-Change from baseline
measured at baseline and 16 weeks
Time frame: 16 weeks
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Virginia